AssayIndex

HYB-2601-N5184

Larazotide acetate · 5 mg declared · Shenzhen Hybio Pharmaceutical Co., Ltd. · manufactured 20 Jan 2026

CHARACTERISED
Lot code
HYB-2601-N5184
Supplier
HYB — Shenzhen Hybio Pharmaceutical Co., Ltd.
Compound
Larazotide acetate
Compound class
Tissue-repair and immunomodulatory peptides
Declared label claim
5mg
Manufacture date
20 Jan 2026
Index quarter
2026-Q1
Independent assays
8
Laboratories involved
Janoshik, VendorInvestigate, Medutest, Kestrel
Provenance mix
Buyer-sourced ×7 · Laboratory-retained ×1
Section 1

Reproducibility across independent tests

Every report below is an observation of the same physical material. What they disagree about is measurement; what they agree about is the lot. The size of the disagreement is compared against what the contributing laboratories' own repeatability figures predict.

Independent assays 8
Median purity 99.70% n=8
Spread (max − min) 0.42pp n=8
Standard deviation 0.147pp n=8
99.499.599.699.799.899.9100.0This lot (HYB-2601-N5184)This lot (HYB-2601-N5184): Q1 99.56, median 99.69, Q3 99.77, n=8n=8All Larazotide acetateAll Larazotide acetate: Q1 99.56, median 99.69, Q3 99.77, n=8n=8 Purity (% area)
Figure 1. This lot's independent purity results against the whole Larazotide acetate record set in the index. The vertical line is the index acceptance specification for the tissue-repair and immunomodulatory peptides class, 98.5 % area. A narrow box on the top row against a wide box on the bottom row is the ideal reading: it means the disagreement between lots is much larger than the disagreement within this one.
Section 2

Member reports 8

Every report the index holds on this lot. Each is a page carrying its own chromatogram, mass spectrum, mass balance, provenance and caveats.

ReportLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-041974HYB-2601-N5184Janoshik2026-Q199.526.11Buyer-sourced0PASS
AX-2026-041975HYB-2601-N5184Janoshik2026-Q199.465.46Buyer-sourced1MARGINAL
AX-2026-041976HYB-2601-N5184VendorInvestigate2026-Q199.586.1091.8Buyer-sourced0PASS
AX-2026-041977HYB-2601-N5184Medutest2026-Q199.885.5091.7Buyer-sourced0PASS
AX-2026-041978HYB-2601-N5184VendorInvestigate2026-Q199.655.68Laboratory-retained0PASS
AX-2026-041979HYB-2601-N5184Medutest2026-Q199.765.89107.4Buyer-sourced0PASS
AX-2026-041980HYB-2601-N5184Janoshik2026-Q199.745.97102.0Buyer-sourced0PASS
AX-2026-041981HYB-2601-N5184Kestrel2026-Q199.815.6099.8Buyer-sourced0PASS
Section 3

By laboratory

Where more than one laboratory assayed this lot, the difference between them is a paired observation of their relative bias — the same material, the same time window, different instruments. Those pairs are what the index's bias estimates are built from.

LaboratoryReportsPurity results (% area)MedianGradientPublished bias (pp)Bias-adjusted
Janoshik399.52, 99.46, 99.7499.5230min+0.0099.52
VendorInvestigate299.58, 99.6599.6232min-0.1199.73
Medutest299.88, 99.7699.8225min+0.0899.74
Kestrel199.8199.8115min+0.2499.57

This lot contributes 6 paired comparisons to the inter-lab analysis.

Section 4

The supplier's certificate for this lot

One number the supplier wrote, beside the median of the numbers other people measured on the same physical material. That comparison is only available because the index groups by lot.

FigureSupplier COAThis reportIndex note
Purity (% area)99.7099.52divergence 0.00 pp vs batch median
Total impurities (% area)0.300.48
Largest single impurity (% area)not stated0.34
Water (%)4.46.11
Counter-ion (%)not stated7.49
Peptide content (%w/w)not statednot determined
Endotoxin (EU/mg)0.27not determined
Method stated on certificateYEScolumn, gradient and wavelength given
Section 5

Impurity fingerprint

The named impurities reported across this lot's assays, with how consistently each was seen. A fingerprint is what allows two lot numbers held by different companies to be identified as one bulk.

Named impurityReported inMedian % areaRange
des-Gly truncate (−57 Da)8 / 80.210.05–0.36
acetyl adduct (+42 Da)8 / 80.080.05–0.11
diketopiperazine (−18 Da)8 / 80.030.02–0.05
[D-Pro]-diastereomer5 / 80.020.01–0.04
Section 7

What this rollup does not establish